IP Verse

A Stable Liquid Formulation Of Fusion Protein With Igg Fc Domain - EP3824879

EP3824879

ALTEOGEN
Application Number
EP20195634A
Filing Date
Jun 23, 2016
Status
Granted And Under Opposition
Oct 25, 2024
Grant Date
Nov 27, 2024
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3824879B1 was granted to Alteogen on Nov 27, 2024 following the initial filing on Jun 23, 2016 under the application number EP20195634A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DORRIESAug 25, 2025ADMISSIBLE
STORZJul 18, 2025ADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2007149334
OPPOSITIONCA2962480
OPPOSITIONJP2016088897
OPPOSITIONUS2006217311
OPPOSITIONUS2014323983
OPPOSITIONUS2015017163
OPPOSITIONWO03009817
OPPOSITIONWO2004055164
OPPOSITIONWO2006044908
OPPOSITIONWO2006104852
OPPOSITIONWO2007092772
OPPOSITIONWO2008086395
OPPOSITIONWO2015006734
OPPOSITIONWO2016045626
OPPOSITIONWO2017129685
SEARCHUS2006217311
SEARCHUS2015017163

Non-Patent Literature (NPL) Citations (25) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Antibodies, (20130000), vol. 2, pages 452 - 500-
DESCRIPTION- Biol. Ther., (20120000), vol. 2, no. 3, pages 1 - 22-
DESCRIPTION- Drug Design Development and Therapy, (20130000), vol. 3, no. 7, pages 711 - 722-
DESCRIPTION- J. Korean Med. Assoc., (20140000), vol. 57, no. 7, pages 614 - 6231-
DESCRIPTION- NEJM, (20150000), vol. 372, no. 13, pages 1193 - 1203-
OPPOSITION- Anonymous, "ARCALYST TM (rilonacept) Injection for Subcutaneous Use - HIGHLIGHTS OF PRESCRIBING INFORMATION ", FDA, (20080201), XP093309883-
OPPOSITION- Anonymous, "EYLEA® (aflibercept) Injection For Intravitreal Injection - HIGHLIGHTS OF PRESCRIBING INFORMATION", FDA, (20141001), XP093309877-
OPPOSITION- Anonymous, "Lucentis 10 mg/ml solution for injection - ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS", EMA, (20111214), EMA, URL: https://ec.europa.eu/health/documents/community-register/2016/20161114136324/anx_136324_en.pdf, XP093309875-
OPPOSITION- Anonymous, "LUCENTIS (ranibizumab injection) Intravitreal Injection - HIGHLIGHTS OF PRESCRIBING INFORMATION ", FDA, (20141001), FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s105lbl.pdf, XP093309886-
OPPOSITION- Anonymous, " Schüttgüter Schüttdichte - Schüttgewicht", MOLLET FÜLLSTANDTECHNIK GMBH, (20220201), MOLLET FÜLLSTANDTECHNIK GMBH, URL: https://www.mollet.de/uploads/tx_cinproducts/00-0_AI_Schuettdichte_AI-SG-00_02-22_de.pdf, XP093309872-
OPPOSITION- D27 - Summons to oral proceedings in the prosecution of the application underlying then patent in dispute 19 October 2023-
OPPOSITION- "FORMULATION OF PROTEIN- AND PEPTIDE-BASED PARENTERAL PRODUCTS", Sandeep Nema, John D. Ludwig, Pharmaceutical Dosage Forms Parenteral Medications, Third Edition, Volume 1 Formulation and Packaging, informa healthcare, (2010), page 235, ISBN 9781420086430-
OPPOSITION- Semeraro F, Et Al., "Aflibercept in wet AMD: specific role and optimal use", DRUG DESIGN, DEVELOPMENT AND THERAPY, (20130101), vol. 7, XP055971638-
OPPOSITION- Sampathkumar Krishnan, Monica M. Pallitto, Margaret S. Ricci, "Development of Formulations for Therapeutic Monoclonal Antibodies and Fc Fusion Proteins", Sampathkumar Krishnan, Monica M. Pallitto, Margaret S. Ricci, Feroz Jameel, Susan Hershenson, Formulation and process development strategies for manufacturing biopharmaceuticals., New York , Wiley , (20100726), pages 383 - 427, doi:10.1002/9780470595886.ch16, ISBN 9780470118122, XP055188652
OPPOSITION- Wei Wang , Satish Singh, David L Zeng, Kevin King, Sandeep Nema, "Antibody structure, instability, and formulation", Journal of pharmaceutical sciences, Elsevier Inc, (20070101), vol. 96, no. 1, doi:10.1002/jps.20727, ISSN 0022-3549, pages 1 - 26, XP009084505
OPPOSITION- T. Arakawa ; K. Tsumoto ; Y. Kita ; B. Chang ; D. Ejima, "Biotechnology applications of amino acids in protein purification and formulations", Amino Acids ; The Forum for Amino Acid and Protein Research, Springer-Verlag, Vi, Vi , (20070316), vol. 33, no. 4, doi:10.1007/s00726-007-0506-3, ISSN 1438-2199, pages 587 - 605, XP019565540
OPPOSITION- Nicholas W. Warne, "Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development", European journal of pharmaceutics and biopharmaceutics, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, NL , (20110601), vol. 78, no. 2, doi:10.1016/j.ejpb.2011.03.004, ISSN 0939-6411, pages 208 - 212, XP055534222
OPPOSITION- CHEN BEI,ET AL, "Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.", Pharmaceutical Research, Springer Berlin Heidelberg, Berlin/Heidelberg, Berlin/Heidelberg, (20031201), vol. 20, no. 12, doi:10.1023/B:PHAM.0000008042.15988.c0, ISSN 0724-8741, pages 1952 - 1960, XP002386671
OPPOSITION- Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S, "Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature", EYE, Nature Publishing Group, GB, GB , (20100501), vol. 24, no. 5, doi:10.1038/eye.2009.219, ISSN 0950-222X, pages 816 - 824, XP093309843
OPPOSITION- Stewart Michael W., Grippon Seden, Kirkpatrick Peter, "Aflibercept", Nature Reviews Drug Discovery, Nature Publishing Group, GB, GB , (20120401), vol. 11, no. 4, doi:10.1038/nrd3700, ISSN 1474-1776, pages 269 - 270, XP093309803
OPPOSITION- Mansour Ahmad M, Al-Ghadban Sara I, Yunis Muhammad H, El-Sabban Marwan E, "Ziv-aflibercept in macular disease", BRITISH JOURNAL OF OPHTHALMOLOGY, BMJ Publishing Group, GB, GB , (20150801), vol. 99, no. 8, doi:10.1136/bjophthalmol-2014-306319, ISSN 0007-1161, pages 1055 - 1059, XP093309850
OPPOSITION- De Oliveira Dias João Rafael, De Andrade Gabriel Costa, Novais Eduardo Amorim, Farah Michel Eid, Rodrigues Eduardo Büchele, "Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept", International Journal of Retina and Vitreous, (20161201), vol. 2, no. 1, doi:10.1186/s40942-016-0026-y, page 3, XP055927160
OPPOSITION- Meyer Brian K., Shameem Mohammed, "Commercial therapeutic protein drug products", Therapeutic Protein Drug Products, Elsevier, (20120101), pages 1 - 11, doi:10.1533/9781908818102.1, ISBN 978-1-907568-18-3, XP093309796
OPPOSITION- Sumit Goswami, Wei Wang, Tsutomu Arakawa, Satoshi Ohtake, "Developments and Challenges for mAb-Based Therapeutics", Antibodies, vol. 2, no. 3, doi:10.3390/antib2030452, pages 452 - 500, XP055128980
OPPOSITION- Moradi Ahmadreza, "Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema", World Journal of Diabetes, (20130101), vol. 4, no. 6, doi:10.4239/wjd.v4.i6.303, ISSN 1948-9358, page 303, XP093309849

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents